ADMA Biologics raises FY2023 revenue guidance to >$240M; Q2 revenue up 77% to $60.1M

ADMA BIOLOGICS, INC.

2023-Q2 EPS reported -$0.06 revenue$117,036,725

Q2 2023 total revenues $60.1M (+77% YoY); gross margin 27.8% (vs. 22.9% Q2 2022); normalized margin 31-32% excl. IT disruption.
Adjusted EBITDA $6.4M vs. -$6.3M YoY; net loss narrowed to $6.4M from $13.8M; adjusted net loss $3.6M.
FY2023 revenue guidance raised to at least $240M (from $220M); FY2024 raised to $275M; FY2025 to $325M+.
Nonrecurring IT disruption charge of $2.8M in COGS; production has resumed; # of FDA-licensed plasma centers on track for 10 by year-end.
Terminated financial advisory agreement with Morgan Stanley; continues to evaluate strategic alternatives.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. reported the three months ended June 30, 2023 results: revenue $60.1 Million. Guidance raised.

Period: the three months ended June 30, 2023
Revenue: $60.1 Million
Guidance: raised
Result: reported results

Exact text from the filing

2 brhc20057230_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update 2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss(2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. reported FY2023 results: revenue $240 Million. Guidance raised.

Period: FY2023
Revenue: $240 Million
Guidance: raised
Result: guidance update

Exact text from the filing

FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. reported FY2025 results: revenue $325 Million. Guidance raised.

Period: FY2025
Revenue: $325 Million
Guidance: raised
Result: guidance update

Exact text from the filing

FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADMA BIOLOGICS, INC. reported FY2024 results: revenue $275 Million. Guidance raised.

Period: FY2024
Revenue: $275 Million
Guidance: raised
Result: guidance update

Exact text from the filing

FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively

View on SEC.gov

Browse all earnings releases →

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-23-038803

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.